ASKP1240, a fully human anti-CD40 monoclonal antibody, prolongs pancreatic islet allograft survival in nonhuman primates

American Journal of Transplantation

Volumn 13, Issue 8, 2013, Pages 1976-1988

  Watanabe, M ^a   Yamashita, K ^a   Suzuki, T ^a   Kamachi, H ^a   Kuraya, D ^a   Koshizuka, Y ^a   Ogura, M ^a   Yoshida, T ^a   Aoyagi, T ^a   Fukumori, D ^a   Shimamura, T ^b   Okimura, K ^c   Maeta, K ^c   Miura, T ^c   Sakai, F ^d   Todo, S ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^c KYOWA HAKKO KOGYO CO LTD   (Japan)

^d ASTELLAS PHARMA INC   (Japan)

Author keywords

Co stimulation blockade; monoclonal antibodies; nonhuman primates; pancreatic islet transplantation

Indexed keywords

ASKP 1240; C PEPTIDE; CD40 ANTIGEN; GLUCOSE; HUMAN INSULIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GRAFT SURVIVAL; HAPLORHINI; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PANCREAS RESECTION; PHENOTYPE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; T LYMPHOCYTE;

CO-STIMULATION BLOCKADE; MONOCLONAL ANTIBODIES; NONHUMAN PRIMATES; PANCREATIC ISLET TRANSPLANTATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CD40 LIGAND; DIABETES MELLITUS, TYPE 1; GRAFT SURVIVAL; HUMANS; IMMUNE TOLERANCE; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MACACA FASCICULARIS; MALE; PANCREATECTOMY; TISSUE DISTRIBUTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84881371133     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12330     Document Type: Article

References (53)

1. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230-238.
2. Barton FB, Rickels MR, Alejandro R, et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care 2012; 35: 1436-1445.
3. Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005; 293: 830-835.
4. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060-2069.
5. Matas AJ, Gillingham KJ, Humar A, et al. Posttransplant diabetes mellitus and acute rejection: Impact on kidney transplant outcome. Transplantation 2008; 85: 338-343.
6. Ryan EA, Lakey JR, Rajotte RV, et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 2001; 50: 710-719.
7. Bell E, Cao X, Moibi JA, et al. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes 2003; 52: 2731-2739.
8. Nir T, Melton DA, Dor Y., Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 2007; 117: 2553-2561.
9. Zhang N, Su D, Qu S, et al. Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes 2006; 55: 2429-2436.
10. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5: 686-693.
11. Barnhart B, Ford GS, Bhushan A, Song C, Covey LR., A polymorphic CD40 ligand (CD154) molecule mediates CD40-dependent signalling but interferes with the ability of soluble CD40 to functionally block CD154: CD40 interactions. Immunology 2000; 99: 54-61.
12. Kenyon NS, Chatzipetrou M, Masetti M, et al. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci USA 1999; 96: 8132-8137.
13. Kenyon NS, Fernandez LA, Lehmann R, et al. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. Diabetes 1999; 48: 1473-1481.
14. Koulmanda M, Smith RN, Qipo A, Weir G, Auchincloss H, Strom TB., Prolonged survival of allogeneic islets in cynomolgus monkeys after short-term anti-CD154-based therapy: Nonimmunologic graft failure ? Am J Transplant 2006; 6: 687-696.
15. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB., Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000; 6: 114.
16. Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002; 8: 247-252.
17. Adams AB, Shirasugi N, Jones TR, et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol 2005; 174: 542-550.
18. Badell IR, Thompson PW, Turner AP, et al. Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates. Am J Transplant 2012; 12: 126-135.
19. Badell IR, Russell MC, Cardona K, et al. CTLA4Ig prevents alloantibody formation following nonhuman primate islet transplantation using the CD40-specific antibody 3A8. Am J Transplant 2012; 12: 1918-1923.
20. Lowe M, Badell IR, Thompson P, et al. A novel monoclonal antibody to CD40 prolongs islet allograft survival. Am J Transplant 2012; 12: 2079-2087.
21. Imai A, Suzuki T, Sugitani A, et al. A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys. Transplantation 2007; 84: 1020-1028.
22. Aoyagi T, Yamashita K, Suzuki T, et al. A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: Induction and maintenance therapy. Am J Transplant 2009; 9: 1732-1741.
23. Oura T, Yamashita K, Suzuki T, et al. Long-term hepatic allograft acceptance based on CD40 blockade by ASKP1240 in nonhuman primates. Am J Transplant 2012; 12: 1740-1754.
24. Yoshida T, Suzuki T, Watanabe M, et al. Induction of insulin-dependent diabetes mellitus by total pancreatectomy for pancreatic islet transplantation in cynomolgus monkeys. J Hepatobiliary Pancreat Sci 2012; 19: 661-666.
25. Ericzon BG, Wijnen RM, Kubota K, vd Bogaard A, Kootstra G., Diabetes induction and pancreatic transplantation in the cynomolgus monkey: Methodological considerations. Transpl Int 1991; 4: 103-109.
26. Ricordi C, Gray DW, Hering BJ, et al. Islet isolation assessment in man and large animals. Acta Diabetol Lat 1990; 27: 185-195.
27. Wetekam W, Groneberg J, Leineweber M, Wengenmayer F, Winnacker EL., The nucleotide sequence of cDNA coding for preproinsulin from the primate Macaca fascicularis. Gene 1982; 19: 179-183.
28. Rabinovitch A, Alejandro R, Noel J, Brunschwig JP, Ryan US., Tissue culture reduces Ia antigen-bearing cells in rat islets and prolongs islet allograft survival. Diabetes 1982; 31 (Suppl. 4): 48-54.
29. Ketchum RJ, Moore WV, Hegre OD., Increased islet allograft survival after extended culture by a mechanism other than depletion of donor APCs. Lack of correlation between the elimination of donor MHC class II-positive accessory cells and increased transplantability. Transplantation 1992; 54: 347-351.
30. Kuttler B, Hartmann A, Wanka H., Long-term culture of islets abrogates cytokine-induced or lymphocyte-induced increase of antigen expression on beta cells. Transplantation 2002; 74: 440-445.
31. Pons JA, Revilla-Nuin B, Baroja-Mazo A, et al. FoxP3 in peripheral blood is associated with operational tolerance in liver transplant patients during immunosuppression withdrawal. Transplantation 2008; 86: 1370-1378.
32. Martinez-Llordella M, Puig-Pey I, Orlando G, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007; 7: 309-319.
33. Martinez-Llordella M, Lozano JJ, Puig-Pey I, et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008; 118: 2845-2857.
34. Newell KA, Asare A, Kirk AD, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010; 120: 1836-1847.
35. Sagoo P, Perucha E, Sawitzki B, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010; 120: 1848-1861.
36. Boon L, Laman JD, Ortiz-Buijsse A, et al. Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys. Toxicology 2002; 174: 53-65.
37. Han D, Xu X, Baidal D, et al. Assessment of cytotoxic lymphocyte gene expression in the peripheral blood of human islet allograft recipients: Elevation precedes clinical evidence of rejection. Diabetes 2004; 53: 2281-2290.
38. Han D, Xu X, Pastori RL, Ricordi C, Kenyon NS., Elevation of cytotoxic lymphocyte gene expression is predictive of islet allograft rejection in nonhuman primates. Diabetes 2002; 51: 562-566.
39. Thompson P, Cardona K, Russell M, et al. CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates. Am J Transplant 2011; 11: 947-957.
40. Posselt AM, Bellin MD, Tavakol M, et al. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am J Transplant 2010; 10: 1870-1880.
41. Tan J, Yang S, Cai J, et al. Simultaneous islet and kidney transplantation in seven patients with type 1 diabetes and end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction. Diabetes 2008; 57: 2666-2671.
42. Froud T, Baidal DA, Faradji R, et al. Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes. Transplantation 2008; 86: 1695-1701.
43. Hering BJ, Kandaswamy R, Harmon JV, et al. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant 2004; 4: 390-401.
44. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ., T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393: 480-483.
45. Ford ML, Larsen CP., Translating costimulation blockade to the clinic: Lessons learned from three pathways. Immunol Rev 2009; 229: 294-306.
46. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434-438.
47. Nomura M, Yamashita K, Murakami M, et al. Induction of donor-specific tolerance by adenovirus-mediated CD40Ig gene therapy in rat liver transplantation. Transplantation 2002; 73: 1403-1410.
48. Yamashita K, Masunaga T, Yanagida N, et al. Long-term acceptance of rat cardiac allografts on the basis of adenovirus mediated CD40Ig plus CTLA4Ig gene therapies. Transplantation 2003; 76: 1089-1096.
49. Terasaki PI., Humoral theory of transplantation. Am J Transplant 2003; 3: 665-673.
50. Campbell PM, Salam A, Ryan EA, et al. Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation. Am J Transplant 2007; 7: 1242-1248.
51. Campbell PM, Senior PA, Salam A, et al. High risk of sensitization after failed islet transplantation. Am J Transplant 2007; 7: 2311-2317.
52. van Essen D, Kikutani H, Gray D., CD40 ligand-transduced co-stimulation of T cells in the development of helper function. Nature 1995; 378: 620-623.
53. McAdam AJ, Greenwald RJ, Levin MA, et al. ICOS is critical for CD40-mediated antibody class switching. Nature 2001; 409: 102-105.